Sell RIM!: Against ...
Health Care: Drugs
ARCA biopharma Inc. (ABIO: NASDAQ)
$0.48 -0.02 | -3.81%
06/04/12 - 01:42 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.94 | 0.58 | 0.98 |
| Price to Sales (TTM) | 0.00 | 4.62 | 1.42 |
| Price to Book (MRQ) | 1.40 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 1.40 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -1.50 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -0.90 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | n.a. | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 7.10 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 7.90 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -344.33 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | n.a. | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -92.10 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -30.90 | 2.20 | 2.50 |
| Return on Investment (TTM) | -104.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -50.10 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 0.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -415,000.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with ABIO
- Portfolio NameUser Type
- Userbuddy62370 Portfolio 1
- UserKumaran
- UserSUPRATRADE NEW-BUY LIST-240...
Latest ABIO Headlines from TheStreet
- InfoLogix, Netlist: Midday Volume Plays 05.17.10 | 01:05 pm
- Arca BioPharma Patent Deja Vu: BioBuzz 03.29.10 | 06:03 am
- Sirius XM, ARCA biopharma: Early Volume Plays 03.26.10 | 09:03 am
- Brazilian Telecom, Agria: Midday Volume Plays 11.24.09 | 01:11 pm
- ARCA, FortuNet: Midday Volume Plays 11.23.09 | 01:11 pm
- Funds Sell $4M Worth of Pain Therapeutics 06.11.09 | 09:06 am
- Ford, Deere, Cisco Systems Are Big Movers 06.01.09 | 05:06 pm
- FDA Wants ARCA To Run More Tests On Heart Drug 06.01.09 | 11:06 am
- The Second Dendreon Wave
05.18.09 | 02:05 pm
Press Releases for ABIO
- GencaroTM's Norepinephrine Lowering Likely Contributes To Its Effect In Atrial Fibrillation Prevention - Business Wire 03.26.12 | 12:03 pm
- GencaroTM Atrial Fibrillation Data Selected For Presentation At American College Of Cardiology 61st Annual Scientific Session & Expo - Business Wire 03.20.12 | 08:03 am
- ARCA Biopharma Announces Additional Patent Issued For Methods For Treatment With Bucindolol Based On Genotype Of Patient - Business Wire 01.19.12 | 08:01 am
- CEO Of ARCA Biopharma To Speak On Use Of Biomarkers And Implications Of Personalized Medicine At New Paradigms Conference On January 12, 2012 - Business Wire 01.05.12 | 08:01 am
- Dr. Michael Bristow, CEO, ARCA Biopharma (Photo: Business Wire) - Business Wire 12.30.11 | 08:12 am
- ARCA Biopharma Announces Private Placement Of $1.75 Million With Institutional Investors - Business Wire 12.22.11 | 08:12 am
- Kaplan Meier Curves By Beta-1 389 Arg/Gly Polymorphism. (Graphic: Business Wire) - Business Wire 11.16.11 | 11:11 am
- Dr. Michael Bristow, CEO, ARCA Biopharma (Photo: Business Wire) - Business Wire 11.11.11 | 08:11 am
- Two GencaroTM Atrial Fibrillation Abstracts Accepted For Presentation At The American Heart Association Scientific Sessions 2011 - Business Wire 08.10.11 | 08:08 am
- ARCA Biopharma Announces Planned Expansion Of Gencaro Development To Atrial Fibrillation - Business Wire 05.26.11 | 08:05 am
Partner Headlines for ABIO
- Will the Next Apple or Google Be Found Among These Micro Caps? - Seeking Alpha 08.18.11 | 09:08 am
- Top Percentage Gainers and Losers as of 2pm 05/13/11 (ABIO, GFRE, DDS, APL, DF, VRML, DAR, SWSH, ONTY, GS, RMBS, LPHI, GGS, CA, NVDA, IMRS, MNTX, MPG, GTY) - Benzinga 05.13.11 | 02:05 pm
- Morning Market Movers (ABIO, LBIX, CGNX, AEIS) - Benzinga 05.03.11 | 09:05 am
- UPDATE 1-Arca reaches agreement with FDA on heart-drug study - Reuters 05.17.10 | 09:05 am
- UPDATE 1-ARCA gets U.S. patent related to heart drug; shrs soar - Reuters 03.26.10 | 10:03 am
